CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
July 2015—Pathology Associates Medical Laboratories has entered into a collaborative agreement with Axela to develop multiplex assays focused on immune status for vaccine preventable diseases. These serologic assays will measure antibodies to a wide range of viruses including measles, mumps, and rubella as an aid in the determination of patient immunity. Based on Axela’s new generation of flow-through arrays, these highly sensitive assays require a single microliter of sample. The agreement also calls for expansion of the offering to a range of multiplex targets beyond the initial serological assays. PAML will provide the tests exclusively in the U.S., while Axela will have the option to commercialize its benchtop analyzer and point-of-use formats throughout the rest of the world.
PAML, 800-541-7891